Trabectedin: Supportive care strategies and safety profile.

Abstract

Trabectedin is an approved antineoplastic agent for the treatment of adult patients with advanced soft tissue sarcomas or in combination with pegylated liposomal doxorubicin (PLD) in patients with relapsed platinum sensitive ovarian cancer. The mechanism of action is still not fully understood but many typical side effects seen with other chemotherapy drugs are less common, mild or unreported. Although this apparent favorable safety profile suggests a well-tolerated and manageable therapeutic option in the palliative care setting, trabectedin does have specific adverse side effects which can be hazardous for individual patients. The most commonly observed toxicities with trabectedin include neutropenia, nausea, vomiting, and increases in liver transaminases, anemia, fatigue, thrombocytopenia, anorexia and diarrhea. However, for most patients the appropriate use of supportive care strategies can reduce or overcome these side effects. We present a concise review of the safety data of trabectedin with the corresponding overview of the supportive care strategies.

• Authors: Karin Jordan, Franziska Jahn, Berit Jordan, Thomas Kegel, Carsten Müller-Tidow, Jörn Rüssel
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 94 Issue 3 Pg. 279-90 (Jun 2015) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 25794812 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents, Alkylating
• Dioxoles
• Tetrahydroisoquinolines
• Trabectedin

Topics

• Antineoplastic Agents, Alkylating (administration & dosage, adverse effects, therapeutic use)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Dioxoles (administration & dosage, adverse effects, therapeutic use)
• Drug-Related Side Effects and Adverse Reactions
• Female
• Humans
• Male
• Neoplasms (drug therapy)
• Ovarian Neoplasms (drug therapy)
• Sarcoma (drug therapy)
• Tetrahydroisoquinolines (administration & dosage, adverse effects, therapeutic use)
• Trabectedin